# NCT05870319 (NCT05870319)

> A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05870319
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Non-small Cell Lung Cancer
- Interventions: SKB264; Pemetrexed; Carboplatin; Cisplatin
- Enrollment: 376
- Primary outcome: Progression-free survival (PFS)

## Commentary we found

- Podcasts: 3
- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05870319